Skip to main content

Advertisement

Table 1 Demographics and baseline characteristics (FAS P1 , FAS P2 )

From: Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study

PERIOD 1
  Placebo 300IR
N = 261 N = 275
Age (years) 36.6 (11.26) 38.6 (10.97)
Gender (n and % female) 137 (52.5) 141 (51.3)
Duration of allergic rhinoconjunctivitis (years) 13.7 (10.72) 14.2 (10.52)
Presence of Oral Allergy Syndrome (n, %) 141 (54.0) 150 (54.5)
FEV1 (% predicted) 100.7 (11.82) 101.8 (13.80)
RRTSS 14.2 (1.62) 14.4 (1.75)
Presence of asthma (n, %) 75 (28.7) 58 (21.1)
Poly-sensitized* (n, %) 179 (68.6) 205 (74.5)
PERIOD 2
  Placebo 300IR
N = 247 N = 253
Age (years) 36.7 (11.33) 38.4 (11.05)
Gender (n and % female) 129 (52.2) 132 (52.2)
Duration of allergic rhinoconjunctivitis (years) 13.4 (10.39) 13.8 (10.49)
Presence of Oral Allergy Syndrome (n, %) 133 (53.8) 138 (54.5)
FEV1 (% predicted) 100.8 (12.05) 102.1 (13.58)
RRTSS 14.2 (1.60) 14.4 (1.75)
Presence of asthma (n, %) 70 (28.3) 54 (21.3)
Poly-sensitized* (n, %) 169 (68.4) 185 (73.1)
  1. Results describing continuous variables are expressed as means (SDs). Results describing categorical variables are expressed as the number of patients and the percentage relative to the number of patients in the FASP1 and FASP2 with non-missing data.
  2. RRTSS = Retrospective Rhinoconjunctivitis Total Symptom Score.
  3. *Sensitized to birch pollen and at least one other allergen tested.